Sorrento Therapeutics

Sorrento Therapeutics is a development-stage biopharmaceutical company focused on the acquisition, discovery, development, and commercialization of proprietary drug therapies to address significant unmet medical needs. We have generated human antibodies against many important targets in cancer treatment, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, and many other targets at various stages of development. Our CAR-T programs include the clinical-stage CD38 CAR T. Combination approaches are being evaluated in preclinical stages for multiple myeloma, lung cancer, and other adult and pediatric cancers.